Cargando…
Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer
SIMPLE SUMMARY: Breast cancer outcomes are variable due to differences in tumor biology, patient biology, and treatment. The likelihood of developing cancer and other diseases increases with age. Thus, many patients with breast cancer have multiple co-morbidities requiring medical management, which...
Autores principales: | Bernard, Philip S., Wooderchak-Donahue, Whitney, Wei, Mei, Bray, Steven M., Wood, Kevin C., Parikh, Baiju, McMillin, Gwendolyn A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998388/ https://www.ncbi.nlm.nih.gov/pubmed/33799547 http://dx.doi.org/10.3390/cancers13061219 |
Ejemplares similares
-
Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing
por: van der Wouden, Cathelijne H., et al.
Publicado: (2019) -
Efficacy and utility of a protocol for pre-emptive antimycotic therapy
por: Milanov, SG, et al.
Publicado: (2010) -
Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial
por: Stäuble, Céline K., et al.
Publicado: (2021) -
Can Umbilical Cord and Meconium Results Be Directly Compared? Analytical Approach Matters
por: Pandya, Vrajesh, et al.
Publicado: (2022) -
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia
por: Kim, Kibum, et al.
Publicado: (2019)